Scinai Immunotherapeutics Ltd. (SCNI) Financial Ratios
17 years of historical data (2009–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low17.9·High17.9
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.16
↓-99% vs avg
5yr avg: 11.42
30Y Low0.2·High33.8
ROE
↑
-91.9%
↓+63% vs avg
5yr avg: -250.1%
30Y Low-92%·High177%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low7.6·High7.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SCNI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Scinai Immunotherapeutics Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $714770 | $2M | $3M | $2M | $6M | $33M | $31M | $76M | $31M | $27M | $11M |
| Enterprise Value | $1M | $2M | $3M | $18M | $13M | $45M | $49M | $93M | $36M | $6M | $7M |
| P/E Ratio → | -0.15 | — | 0.56 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.55 | 1.27 | 4.11 | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.16 | 0.21 | 0.27 | — | — | 33.78 | — | — | — | 1.67 | 1.70 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SCNI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.73 | 4.29 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | 17.85 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 21.52 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SCNI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Scinai Immunotherapeutics Ltd. earns an operating margin of -575.3%. Operating margins have expanded from -1312.8% to -575.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -91.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -202.3% | -202.3% | -88.1% | — | — | — | — | — | — | — | — |
| Operating Margin | -575.3% | -575.3% | -1312.8% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -633.6% | -633.6% | 728.9% | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -91.9% | -91.9% | 177.4% | — | — | -835.6% | — | — | -600.0% | -87.0% | -31.2% |
| ROA | -66.3% | -66.3% | 31.0% | -29.2% | -19.6% | -33.0% | -5.4% | -102.3% | -90.6% | -63.5% | -25.9% |
| ROIC | -60.1% | -60.1% | -61.1% | -86.5% | -89.5% | -62.1% | 29.5% | — | — | — | -178.8% |
| ROCE | -69.6% | -69.6% | -63.2% | -48.0% | -40.7% | -79.6% | 17.7% | -89.9% | -93.7% | -47.0% | -35.1% |
SCNI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $606000 ($2M total debt minus $2M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.21 | — | — | 29.77 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | 7.60 | — | — | — | — |
| Net Debt / Equity | — | 0.07 | 0.01 | — | — | 12.08 | — | — | — | -1.27 | -0.61 |
| Net Debt / EBITDA | — | — | — | — | — | — | 6.53 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -22.14 | -22.14 | -6.00 | -1216.44 | -2.19 | -3.23 | 6.54 | -5.30 | -5.45 | -332.39 | -30890.00 |
SCNI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.30x means Scinai Immunotherapeutics Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.06x to 1.30x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.30 | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 |
| Quick Ratio | 1.30 | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 |
| Cash Ratio | 1.05 | 1.05 | 1.09 | 2.74 | 6.02 | 7.11 | 0.15 | 3.82 | 3.48 | 10.37 | 18.42 |
| Asset Turnover | — | 0.11 | 0.05 | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 46.77 | 120.37 | — | — | — | — | — | — | — | — |
SCNI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Scinai Immunotherapeutics Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 179.1% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $806368 | $390657 | $188519 | $141144 | $110815 | $81663 | $65355 | $50258 | $33774 |
Peer Comparison
Compare SCNI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SCNIYou | $714770 | -0.2 | — | — | -202.3% | -575.3% | -91.9% | -60.1% | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 DYAI | $27M | -3.7 | — | — | 65.8% | -168.8% | -139.2% | -1669.3% | — |
 IBIO | $26M | -0.9 | — | — | 100.0% | -4650.5% | -101.5% | -130.5% | — |
 VXRT | $178M | 10.6 | 7.4 | 23.5 | — | 7.6% | 22.3% | 27.1% | 0.5 |
 MNOV | $70M | -6.0 | — | — | 7.6% | -3242.5% | -25.5% | -85.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ABCL | $1B | -9.8 | — | — | — | -289.0% | -14.5% | -16.8% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 17 years · Updated daily
See SCNI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCNI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SCNI vs NVAX
Side-by-side business, growth, and profitability comparison vs Novavax, Inc..
Start ComparisonSCNI — Frequently Asked Questions
Quick answers to the most common questions about buying SCNI stock.
What is Scinai Immunotherapeutics Ltd.'s P/E ratio?
Scinai Immunotherapeutics Ltd.'s current P/E ratio is -0.2x. The historical average is 0.6x.
What is Scinai Immunotherapeutics Ltd.'s ROE?
Scinai Immunotherapeutics Ltd.'s return on equity (ROE) is -91.9%. The historical average is -23.4%.
Is SCNI stock overvalued?
Based on historical data, Scinai Immunotherapeutics Ltd. is trading at a P/E of -0.2x. Compare with industry peers and growth rates for a complete picture.
What are Scinai Immunotherapeutics Ltd.'s profit margins?
Scinai Immunotherapeutics Ltd. has -202.3% gross margin and -575.3% operating margin.